Biotech Values

[vinmantoo]

Was gonna pull the trigger on IMGN on May 1st, but thought I could wait for FED update as the management indicated the trial result would be out EARLY May. Have to say May 2nd is indeed EARLY :) congrats on the big gain.

Tony, thanks for the congratulations.

I don't think is it too late to buy into IMGN but you have to pay the cost for the information gained from MIRASOL as IMGN has been de-risked or perhaps greatly reduced in risk. Not only is Elahere in more trials, this time for PSOC (Platinum Sensitive Ovarian Cancer), they have other ADCs including an updated and improved follow up to Elahere, called IMGN151. The pre-clinical data presented so far sure makes IMGN151 look impressive and better than Elahere, as it shows efficacy against low, medium and high alpha foliate expression and has a longer lasting ADC linker. However, these improvements in IMGN151 could affect toxicity so obviously clinical trial data is the key. The phase I trial of IMGN151 is already in progress and its estimated primary completion date is Sept 30, 2023 so is a ways off.

Here is the data.

https://aacrjournals.org/cancerres/article/80/16_Supplement/2890/642251/Abstract-2890-IMGN151-A-next-generation-folate

Here is the phase I trial.

https://clinicaltrials.gov/ct2/show/NCT05527184

Good luck to you!